Search Press releases

Press releases teaser image
4 Feb 2026

UCB showcases three-year hidradenitis suppurativa data at EHSF: BIMZELX[®]▼(bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements

Read More
Press releases teaser image
30 Jan 2026

KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment for Thymidine Kinase 2 Deficiency (TK2d)

Read More
Press releases teaser image
13 Jan 2026

Innovation and Execution Power UCB’s Success

Read More
Press releases teaser image
8 Dec 2025

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

Read More
Press releases teaser image
5 Dec 2025

UCB Upgrades 2025 Financial Guidance Based on Strong Performance

Read More
Press releases teaser image
4 Dec 2025

UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting

Read More

Stay up-to-date on the latest news and information from UCB

Subscribe